ERNA Eterna Therapeutics Inc

Price (delayed)

$3.65

Market cap

$5.96M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$14.1

Enterprise value

$1.28M

Relative Growth: Rel. Growth:
Relative Strength: Rel. Strength:
Relative Valuation: Rel. Valuation:
Relative Profitability: Rel. Profitability: 10

Eterna Therapeutics is a publicly traded, preclinical-stage company focused on using cutting-edge tools to deliver highly innovative, effective, and safe off-the-shelf cell therapies for the treatment of advanced solid tumors, ...

Highlights
Eterna Therapeutics's EPS has soared by 97% YoY and by 46% from the previous quarter
The debt is down by 41% YoY and by 10% QoQ
Eterna Therapeutics's net income has soared by 72% YoY but it has decreased by 8% from the previous quarter
The quick ratio has contracted by 35% from the previous quarter but it has grown by 3% YoY
ERNA's gross profit has dropped by 100% year-on-year
The company's revenue has shrunk by 100% YoY

Key stats

What are the main financial stats of ERNA

ERNA stock price

How has the Eterna Therapeutics stock price performed over time
Intraday
-3.95%
1 week
-6.65%
1 month
-24.9%
1 year
-87.93%
YTD
-87.83%
QTD
-45.11%

Financial performance

How have Eterna Therapeutics's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$13.57M
Net income
-$12.26M
Gross margin
N/A
Net margin
N/A
ERNA's gross profit has dropped by 100% year-on-year
The company's revenue has shrunk by 100% YoY
Eterna Therapeutics's net income has soared by 72% YoY but it has decreased by 8% from the previous quarter
The operating income fell by 16% YoY and by 13% QoQ

Price vs fundamentals

How does ERNA's price correlate with its fundamentals

Growth

What is Eterna Therapeutics's growth rate over time

Valuation

What is Eterna Therapeutics stock price valuation
P/E
N/A
P/B
1.33
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Eterna Therapeutics's EPS has soared by 97% YoY and by 46% from the previous quarter
ERNA's P/B is 75% below its 5-year quarterly average of 5.6 and 42% below its last 4 quarters average of 2.4
ERNA's equity has dropped by 53% since the previous quarter and by 28% year-on-year
The company's revenue has shrunk by 100% YoY

Efficiency

How efficient is Eterna Therapeutics business performance
The ROA has soared by 75% YoY but it has contracted by 12% from the previous quarter
ERNA's return on equity is down by 16% since the previous quarter

Dividends

What is ERNA's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for ERNA.

Financial health

How did Eterna Therapeutics financials performed over time
Eterna Therapeutics's total assets is 103% higher than its total liabilities
Eterna Therapeutics's total assets has decreased by 40% QoQ and by 17% YoY
The quick ratio has contracted by 35% from the previous quarter but it has grown by 3% YoY
The debt is 89% lower than the equity
The debt to equity has soared by 83% from the previous quarter but it has contracted by 15% YoY
ERNA's equity has dropped by 53% since the previous quarter and by 28% year-on-year

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.